@article{Younossi:2026:10.1111/liv.70806,
author = {Younossi, ZM and Papatheodoridis, G and Tsochatzis, E and Buti, M and Rimassa, L and Pinzani, M and Lleo, A and Shawcross, D and Tacke, F and Wong, VW-S and Zelber-Sagi, S and Kremer, AE and J, Pinato D and M, Llovet J and Angeli, P and Asselah, T and Pugliese, N and Caussy, C and Berzigotti, A and Lampertico, P and Cornberg, M and Israelsen, M and Gines, P and Lens, S and Hagström, H and Trauner, M and Brennan, P and Boursier, J and Brunetto, M and Thursz, M and Bugianesi, E and Carette, C and Degasperi, E and Durand, F and Dufour, J-F and Francque, S and Francoz, C and Gautier, J-F and Hernandez-Evole, H and Jones, D and Michel, M and Moreno, C and Mouillot, T and Parlati, L and Pawlotsky, J-M and Rautou, P-E and Reiberger, T and Roux, O and Betel, M and Thabut, D and Noureddin, M and Vilgrain, V and Vuille-Lessard, E and Yilmaz, Y and Gadano, A and Ratziu, V and Schattenberg, JM and Bataller, R and Serfaty, L and Thiele, M and Aghemo, A and Castera, L},
doi = {10.1111/liv.70806},
journal = {Liver Int},
title = {Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.},
url = {http://dx.doi.org/10.1111/liv.70806},
volume = {46},
year = {2026}
}

Download

TY  - JOUR
AB  - The Paris International Liver Meeting (January 19-21, 2026) brought together leading hepatology experts to discuss transformative advances in chronic liver disease management. The meeting highlighted pivotal developments reflecting the field's evolution from disease characterisation toward precision, mechanism-based therapeutics. Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), were highlighted, marking the transition to an era of approved disease-modifying therapies. Resmetirom and semaglutide are now approved for MASH with F2-F3 fibrosis, with a robust pipeline generating anti-fibrotic signals through FGF21 analogs, pan-peroxisome proliferator-activated receptor (PPAR) agonists, and incretin-based dual and triple agonists. Non-invasive tests have evolved beyond their original diagnostic role to enable prognostic stratification, screening of at-risk populations, treatment selection, and monitoring of therapeutic response. This evolution is not limited to MASLD, but extends to other chronic liver diseases, including primary biliary cholangitis (PBC) and portal hypertension, as highlighted by the recommendations of the Baveno Consensus Workshops. Hepatitis B and D are moving toward functional cure strategies, with simplified HBV treatment algorithms based on fibrosis and viral load, supported by biomarkers for risk stratification and safe treatment discontinuation. In parallel, HDV management is transitioning from a severe disease to one with emerging suppressive and potential curative l through bulevirtide and novel HBsAg-targeting and RNA-silencing therapies, respectively. Management of PBC has advanced with novel PPAR agonists that improve cholestatic biochemistry and pruritus, supported by individualised risk stratification. However, significant treatment gaps persist, with fewer than half of eligible PBC patients receiving second-line therapy, and fatigue remains a
AU  - Younossi,ZM
AU  - Papatheodoridis,G
AU  - Tsochatzis,E
AU  - Buti,M
AU  - Rimassa,L
AU  - Pinzani,M
AU  - Lleo,A
AU  - Shawcross,D
AU  - Tacke,F
AU  - Wong,VW-S
AU  - Zelber-Sagi,S
AU  - Kremer,AE
AU  - J,Pinato D
AU  - M,Llovet J
AU  - Angeli,P
AU  - Asselah,T
AU  - Pugliese,N
AU  - Caussy,C
AU  - Berzigotti,A
AU  - Lampertico,P
AU  - Cornberg,M
AU  - Israelsen,M
AU  - Gines,P
AU  - Lens,S
AU  - Hagström,H
AU  - Trauner,M
AU  - Brennan,P
AU  - Boursier,J
AU  - Brunetto,M
AU  - Thursz,M
AU  - Bugianesi,E
AU  - Carette,C
AU  - Degasperi,E
AU  - Durand,F
AU  - Dufour,J-F
AU  - Francque,S
AU  - Francoz,C
AU  - Gautier,J-F
AU  - Hernandez-Evole,H
AU  - Jones,D
AU  - Michel,M
AU  - Moreno,C
AU  - Mouillot,T
AU  - Parlati,L
AU  - Pawlotsky,J-M
AU  - Rautou,P-E
AU  - Reiberger,T
AU  - Roux,O
AU  - Betel,M
AU  - Thabut,D
AU  - Noureddin,M
AU  - Vilgrain,V
AU  - Vuille-Lessard,E
AU  - Yilmaz,Y
AU  - Gadano,A
AU  - Ratziu,V
AU  - Schattenberg,JM
AU  - Bataller,R
AU  - Serfaty,L
AU  - Thiele,M
AU  - Aghemo,A
AU  - Castera,L
DO  - 10.1111/liv.70806
PY  - 2026///
TI  - Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.
T2  - Liver Int
UR  - http://dx.doi.org/10.1111/liv.70806
UR  - https://www.ncbi.nlm.nih.gov/pubmed/42613687
VL  - 46
ER  - 

Download